Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

(2021) Robert H Shaw et al.   LANCET

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

(2021) Alexandra J. Spencer et al.   Nature Communications

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

(2021) Xinxue Liu et al.   LANCET

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

(2021) Alejandro Jara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

(2021) Shuo Feng et al.   NATURE MEDICINE